CCR Grand Rounds

Description:

For More Information About This Series Contact:
Laura Anthony
Phone: 301-984-7191
E-Mail: Laura.Anthony@matthewsgroup.com
Web:

Series Calendar:
1/27/2009	Brigitte Widemann, MD	Development of Targeted Therapies for Neurofibromatosis Type 1 Related Plexiform Neurofibromas
1/6/2009	Malcolm K. Brenner, MD, PhD	Implementing Cell and Gene Therapies for Cancer in an Academic Setting
11/25/2008	Carol Estwing Ferrans, PhD	Translation Science: Exposing a Deadly Difference
11/18/2008	Cory Abate-Shen, PhD	Modeling Cancer in Mice: Insights into Human Cancer
11/4/2008	David Botstein, PhD	How the Genome and the Computer Have Changed Our View of Cancer
10/28/2008	David T. Scadden, MD	The Stem Cell Niche
10/21/2008	Howard A. Fine, MD	Glioblastoma Initiating/Stem Cells: The Biological and Therapeutic Implications of a Changing Paradigm
10/7/2008	J. Brice Weinberg, MD	Nitric Oxide and Leukemia
9/23/2008	Elise C. Kohn, MD	Translational Trials and Tribulations
9/16/2008	Malcolm K. Brenner, MD, MB, PhD, FRCP, FRCPath	CANCELLED-Implementing Cell and Gene Therapies for Cancer in an Academic Setting
7/1/2008	Snorri S. Thorgeirsson, MD, PhD	Genomic Decoding of Liver Cancer: Mechanistic and Therapeutic Implications
6/24/2008	Lisa M. Coussens, PhD	Tissue-Specific Mechanisms Regulating Inflammation-Associated Epithelial Carcinogenesis
6/10/2008	Bruce E. Johnson, MD	Impact of Genomic Changes on the Treatment of Lung Cancr
5/27/2008	Lee J. Helman, MD	Recent Advances in Ewing's Sarcoma
5/20/2008	Donald W. Kufe, MD	Human MUC1-C Oncoprotein as a Target for Cancer Treatment
5/13/2008	Pamela L. Schwarzberg, MD, PhD	T Lymphocyte Signaling and Primary Immunodeficiencies: Lessons from X-linked Lymphoproliferative Disease
5/6/2008	Xin Wei Wang, PhD	Genomic Perspectives of Human Liver Cancer
4/29/2008	A. Thomas Look, MD	Dissecting Cancer Pathways using the Zebrafish: Autophagy and CHK1-Suppressed Apoptosis
4/22/2008	Karen Dow Meneses, PhD, RN, FAAN	Challenges and Explorations in Cancer Survivorship Research
4/22/2008	Kenneth H. Kraemer,MD	Xeroderma Pigmentosum: When the Lifeguard of the Gene Pool Goes on Strike
4/8/2008	Giuseppe Giaccone, MD, PhD	Targets and Targeted Therapy for Lung Cancer
4/1/2008	Stephen B. Baylin, MD	Gene Silencing and the Cancer Epigenome: Biology and Translational Implications
3/25/2008	Francis S. Collins, MD, PhD	The Cancer Genome Atlas Project
3/18/2008	Stephen J. Elledge, PhD	Adventures in Mammalian Genetics
3/11/2008	Carl Wu, PhD	Chromatin Architecture of Chromosome Centromere in Budding Yeast
2/26/2008	Andrea Califano, Dr.	Cancer Systems Biology Comes of Age: Using Molecular Interaction Networks to Dissect Master Regulators of Malignant Transformations
2/19/2008	Donal Small, MD, PhD	Targeting FLT3 for Novel Therapy of Leukemia
2/12/2008	W. Marston Linehan, MD	The Genetic Basis of Kidney Cancer: The Foundation for Disease-Based Therapy
1/29/2008	Frank J. Gonzalez, PhD	Mechanism of Action of Non-Genotoxic Chemical Carcinogens: Implications for Human Risk Assessment
1/22/2008	Carl H. June, MD	Adoptive Transfer Strategies: Impacting Tregs and Vaccines
1/15/2008	Charles J. Sherr, MD PhD	The ARF Tumor Suppressor: Role in Stem Cells, Aging and Cancer
12/4/2007	Jay A. Berzofsky, MD, PhD	The Pluripotential Abilities of IL-15 in Vaccines
11/27/2007	Catherine M. Handy, PhD, RN, AOCN	The Future is Bright Yet so Small: Nanotechnology and Cancer Therapy
11/20/2007	Ian F. Tannock, MD, PhD,FRCPC	Limited Drug Distribution and Repopulation as Important and Neglected Causes of Drug Resistance in Solid Tumors
11/13/2007	Jacques Banchereau, PhD	Harnessing Dendritic Cells to Build Cancer Vaccines
11/6/2007	Michael Dean, PhD	Cancer, Inflammation, and Stem Cells
10/30/2007	Mary Carrington, PhD	The Influence of Variation at Immunogenetic Loci on Human Disease
10/23/2007	Kenneth C. Anderson, MD	Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
10/16/2007	Isaiah J. Fidler, DVM, PhD	Targeting the Organ Microenvironment for Treatment of Cancer Metastasis
10/2/2007	Monica Justice, PhD	Mouse Models of Hematologic Diseases
6/26/2007	Barry Kramer, MD, MPH	Lung Cancer Screening: What We Know vs.What Makes Sense
6/19/2007	Thomas A. Waldmann, MD	Passive and Active Immunotherapy of Cancer: A Critical Perspective
6/12/2007	Anil K. Sood, MD	Neuroendocrine Influences on Cancer Metastasis
5/29/2007	Kevin A. Camphausen, MD	Pre-clinical Models in Radiation Oncology
5/22/2007	James L. Abbruzzese, MD, FACP	Are There New Targets for Pancreatic Cancer Therapeutics?
5/15/2007	Timothy R. Billiar, MD	Liver Ischemia/Reperfusion as a Paradigm: Connecting Redox Biology to Inflammation and Organ Injury
5/8/2007	Ronald A. DePinho, PhD	Modeling and Mining Cancer Genomes
5/1/2007	Stephen J. Elledge, PhD	CANCELLED--The Phosphoproteomics of the DNA Damage Response
4/24/2007	Merrill J. Egorin, MD, FACP	The Relevance of Old-Fashioned Clinical Pharmacology to Modern Anticancer Chemotherapy
4/17/2007	Jean Brown, PhD, RN, FAAN	Symptom Management of Cancer-Related Nutritional Problems
4/10/2007	Joan Brugge, PhD	Modeling Cancer in 3 Dimensions
4/3/2007	Katherine A. Jones, PhD	Mechanistic Studies of RNAP II Transcription Elongation
3/27/2007	William G. Nelson, MD, PhD	5-Me-CpG-Binding Domain Proteins and PRostate Cancer Detection, Diagnosis, Prevention, and Treatment
3/20/2007	Kevin Gardner, MD, PhD	Genomic Approaches to Understanding Mechanisms of Gene Regulation: Perspectives from the Bench to the Bedside
3/13/2007	Mina J. Bissell, PhD	Context and Tissue Structure Determine The Pattern of Gene Expression and Phenotype in Normal and Malignant Breast
3/6/2007	Zena Werb, PhD	Deciphering the Tumor Microenvironment During Breast Cancer Progression
2/27/2007	Monica Justice, PhD	Mouse Models of Hematologic Diseases
2/20/2007	Andre Nussenzweig, PhD	Role of the DNA Damage Response in Maintaining Genome Stability
2/13/2007	Merrill J. Egorin, MD, FACP	The Relevance of Old-fashioned Clinical Pharmacology to Modern Anticancer Chemotherapy
2/6/2007	Glenn Merlina, PhD	Modeling the Genesis and Progression of Melanoma in the Mouse
1/30/2007	Charlotte Kuperwasser, PhD	The Use of Novel Zenograft Models to Study Stroma-epithelial Interactions in Breast Cancer
1/23/2007	Margaret Shipp, MD	Molecular Heterogeneity of Large B-Cell Lymphoma: Identificaation of Rational Treatment Targets
1/16/2007	Carole A. Parent, PhD	Gradient Sensing and Signal Relay During Chemotaxis
12/12/2006	Mark Cushman, PhD Purdue University Yves Pommier, MD, PhD NCI/CCR Lab of Medicinal Chemistry	Synthesis and Evaluation of Indenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors: An NCI Intra-and Extra-Mural Partnership
12/5/2006	J. Silvio Gutkind, PhD	Head and Neck Cancer and Signaling Networks: Novel Mechanism-Based Therapies
11/28/2006	Kenneth W. Kinzler	Cancer Genomes: Discovery and Applications
11/21/2006	Donald P. Bottaro, PhD	The Role of Hepatocyte Growth Factor Signaling in Renal Cancer
11/14/2006	Riccardo Dalla-Favera, MD	CANCELLED--Novel Mechanisms of B-Cell Lymphoma Pathogenesis
11/7/2006	Christine Miaskowski, RN, PhD,	Symptom Clusters: The New Frontier in Symptom Management ResearchProfessor
10/31/2006	John Barrett, MD	How Can We Improve the Antileukemic Effect of Allogeneic Stem Cell Transplantation?
10/24/2006	Lee M. Ellis, MD	VEGF Biology: Beyond Angiogenesis
10/10/2006	Peter J. Houghton, PhD	The TOR Pathway in the Pathogenesis and Treatment of Cancer
10/3/2006	Steven K. Libutti, MD	Targeting the Tumor Microenvironment for Cancer Therapy
9/26/2006	Javed Khan, MD	Translational "omics" in Cancer
9/19/2006	Samuel Strober, MD	Harnessing the Power of Graft Anti-tumor Activity after Bone Marrow Transplantation
9/12/2006	Steven M. Larson, MD	Molecular Imaging and Targeted Radiotherapy in Oncology
7/25/2006	Stuart Schreiber, PhD	NCI's Initiative for Chemical Genetics
7/18/2006	Giorgio Trinchieri, MD	Toll-like Receptors and Cancer: Role in Inflammation, Proliferation, and Apoptosis
7/11/2006	John Condeelis, PhD	Mechanisms of Chemotaxis to EGF and How They Determine Metastatic Potential in Breast Cancer
6/27/2006	Paul A. Bunn, Jr., MD	EGFR Tyrosine Kinase Inhibitor for Lung Cancer: Patient Selection and Methods to Overcome Primary Resistance
6/20/2006	Ron McKay, PhD	Notch Signaling Regulates Stem Cell Numbers in Vitro and in Vivo
5/30/2006	Allan Balmain, PhD, FRSE	Mouse Models for the Identification of Human Tumor Susceptibility Genes
5/23/2006	Timothy J. Triche, MD, PhD	Genomic Analysis of Cancer: Improved Diagnosis and Treatment
5/16/2006	Laurel Northouse, PhD,RN, FAAN	The Importance of Families in Cancer Care
5/2/2006	Chi V. Dang, PhD	Global Genomic Mapping of the Myc Target Gene Network and Tumorigenesis
4/25/2006	Louis J. Ignarro, Ph.D.	Nitric Oxide as a Unique Signaling Molecule in Physiology
4/18/2006	Samuel A. Wells, Jr., M.D.	Targeted Therapy for Thyroid Cancer
4/11/2006	Jeffrey N. Strathern, Ph.D.	Palindromic Gene Amplifications--A New Model for Their Origin
3/28/2006	Philip Beachy, PhD	Hedgehog Signaling in Development and Disease
3/21/2006	Timothy D. Veenstra, PhD	Clinical Proteomics: From Discovery to Validation
3/14/2006	Todd R. Golub, MD	Genomic Signatures for Cancer Classification and Drug Discovery
3/7/2006	Peter Greenwald, MD.,Dr.P.H.	Clinical and Lifestyle Approaches to Cancer Prevention
2/21/2006	Richard R. Love, MD	The Case for a Paradigm Shift from Tumor to Host in Adjuvant Treatment of Breast Cancer
2/14/2006	Anthony Atala, MD	Regenerative Medicine: New Approaches to Health Care in the 21st Century
2/7/2006	Ira Pastan, MD	Immunotoxin Therapy of Cancer: Can Success in Treating Hairy Cell Leukemia be Extended to Other Cancers?
1/31/2006	Clifton Leaf	Cancer Epidemiology, Google, and the Dangerous Legacy of GIGO
1/24/2006	Myles A. Brown, MD	Genome-wide Analysis of Steroid Hormone Aaction
1/17/2006	Thomas Misteli, PhD	Beyond the Genome Sequence: Nuclear Architecture in Health and Disease
11/29/2005	Richard M. Caprioli, PhD	The Role of Proteomics in Clinical and Biological Research: Direct Tissue Analysis by Mass Spectrometry
11/22/2005	Paul Meltzer, MD, PhD	Using Genome Technologies to Find Biological Mechanisms in Cancer: Beyond Expression Profiling
11/15/2005	Mark Levine, MD	Ascorbic Acid In Humans: Tight Control and Unexpected Consequences for Cancer Therapy
11/8/2005	Jeffrey M. Trent, PhD	Towards Systems Medicine: Applications in Cancer Therapeutics
11/1/2005	Sriram Subramaniam, PhD	From Molecules to Tissues: Bridging the Imaging Gap with 3D Electron Microscopy
10/25/2005	Angela Brodie, PhD	Aromatase Inhibitors and Breast Cancer: Concept to Clinic
10/11/2005	Phillip A. Sharp, PhD	The Surprising Biology of Short RNAs
10/4/2005	Pamela S. Hinds, PhD, PN, CS	Fatigue in Adolescents with Cancer: From Clinical Complaint to Intervention
9/27/2005	James B. Mitchell, PhD	Chasing Free Radicals: Use of Nitroxide Antioxidants in Cancer Treatment and Prevention
9/20/2005	James O. Armitage, MD	Is Follicular Lymphoma A Curable Disease
9/13/2005	Carlo M. Croce, MD	MicroRNA Genes and Cancer
7/26/2005	David H. Johnson, MD	Targeting Inflammation in Non-Small Cell Lung Cancer
7/19/2005	Max S. Wicha, MD	Stem Cells in Normal Mammary Development and Breast Cancer
7/12/2005	Crystal Mackall, MD	Integrating Immunotherapy into Existing Cancer Therapies: Challenges and Opportunities
6/28/2005	John D. Minna, MD	Molecular Pathogenesis of Lung Cancer With Translation to the Clinic
6/21/2005	Michael Karin, PhD	The IKK Complex at the Crossroads of Inflammation and Cancer
6/7/2005	Usha Menon, PhD, RN	Literacy and Culture: Bridging Communication Gaps with Your Patients
5/31/2005	Peter H. Duesberg, PhD	Aneuploidy and Cancer: From Correlation to Causation
5/24/2005	Sam T. Hwang, MD, PhD	Chemokine Receptors in Organ-Selective Cancer Metastasis
5/10/2005	James P. Allison, PhD	Checkpoint Inhibition: A New Strategy for Tumor Immunotherapy
5/3/2005	Curtis Harris, MD	Chronic Inflammation and Cancer: Radical Causes of Human Cancer
4/26/2005	John T. Schiller, PhD	Recent Advances in Prophylactic HPV/Cervical Cancer Vaccines
4/19/2005	John T. Schiller, PhD	Recent Advances in Prophylactic HPV/Cervical Cancer Vaccines
4/12/2005	Bruce E. Johnson, MD	Impact of EGFR Mutations on the Treatment of Lung Cancer
4/5/2005	Dan Theodorescu, MD, PhD	RhoGDI2--A New Metastasis Suppressor in Bladder Cancer: Discovery and Clinical Translation
3/29/2005	John D. Potter, MD, PhD	Toward the Last Cohort
3/22/2005	Kenneth C. Anderson, MD	Targeting the Myeloma Cell in its Microenvironment
3/15/2005	Cynthia Dunbar, MD- NHLBI Neal G. Copeland, PhD-Mouse Cancer Genetics Program	Of Mice and Monkeys: Stem Cell Immortalization Genes Unmasked
3/8/2005	Peter M. Blumberg, PhD	From Roadside to Bedside: Natural Products Providing a Path to Therapeutic Targets
3/1/2005	Jeffrey S. Rubin, MD, PhD	Keratinocyte Growth Factor: From Basic Research to Clinical Application
2/22/2005	Andrew P. Feinberg, MD, MPH	Epigenetic Mechanisms in Human Disease
2/15/2005	Elias A. Zerhouni, MD	Future of Medical Imaging
2/8/2005	J. Carl Barrett, PhD	Biosystems and Cancer: Implications for Cancer Development and Therapy
2/1/2005	Javed Khan, MD	The Applications of Microarrays and Artificial Intelligence for Diagnosis, Predicting Prognosis and Selection of Therapeutic Targets
1/25/2005	Carter Van Waes, MD, PhD	Nuclear Factor-kappaB in Regulation of Gene Expression and as a Target for Molecular Therapy
1/18/2005	Beverly Teicher, PhD	Newer Cell-based Models and Therapeutic Targets Related to Tumor Vasculature
1/11/2005	Louis M. Staudt, MD, PhD	Molecular Diagnosis and Molecular Targets in Lymphoid Malignancies by Gene Expression Profiling
1/4/2005	Donald S. Coffey, PhD	What Are the Implications of the Common Denominators of Cancer?
12/14/2004	Dr. Christopher Logothetis
11/30/2004	Stephen J. Chanock, MD	SNPing Away at Cancer
11/23/2004	Judith A. Shell, RN, PhD, A.O.C.N.	Symptom Management in Cancer Related Sexual Dysfunction
11/16/2004	Phillip A. Dennis, MD, PhD	Targeting the Akt Pathway for the Prevention or Treatment of Lung Cancer
11/9/2004	Thomas A. Waldmann, MD	IL2 and IL15: Implications for Immunotherapy and the Design of Molecular Vaccines
11/2/2004	Andrei Kozlov, PhD	Tumor Markers and Evolution
10/26/2004	Michael B. Sporn, MD	Chemoprevention of Cancer: New Approaches, New Agents, New Mechanisms
10/19/2004	Allan M. Weissman, MD	Regulating the RINGs, the Battle for Protein Fate
10/12/2004	James H. Doroshow, MD	Reactive Oxygen Metabolism and the Anthracycline Antibiotic Cell Death Program
10/5/2004	Judah Folkman, MD	Can the Angiogenic Switch be Prevented in Human Cancer
9/21/2004	Dr. David Carbone	Molecular Signatures of Lung Cancer
7/27/2004	Elias A. Zerhouni, MD	Future of Medical Imaging
7/20/2004	Steven A. Rosenberg, PhD, MD	The Development of Cell Transfer Immunotherapy for Patients with Cancer
7/13/2004	Andrew von Eschenbach, MD	Progress Toward Eliminating the Suffering and Death Due to Cancer
7/6/2004	Ronald E. Gress, MD	The Interface of Cancer Immunotherapy and Chemotherapy
6/29/2004	James C. Yang, MD	Biological Approaches to the Treatment of Metastatic Renal Cancer
6/22/2004	Ronald D.G. McKay, PhD	The Importance of Embryonic Stem Cells in Science and Medicine
6/15/2004	Stuart A. Aaronson, MD	Cancer Targeting in the 21st Century
6/1/2004	V. Craig Jordan, OBE, PhD, D.Sc	Estrogen-Induced Apoptosis to Kill the Cancer But Not the Patient
5/25/2004	Henry T. Lynch, MD	Lynch Syndrome (HNPCC): Genetic Counseling, Surveillance, Management, and Molecular Genetics
5/18/2004	Robert B. Diasio, MD	The Increasing Importance of Pharmacogenetics/Pharmacogenomics in Cancer Chemotherapy: Lessons from 5-Fluorouracil Research
5/11/2004	Axel Ullrich, PhD	From Gene to Cancer Therapy
4/27/2004	Carl F. Nathan, MD	Inflammation as a Flow of Information
4/20/2004	Martin Abeloff, MD	Adjuvant Therapy of Breast Cancer: The Importance of Incremental Gains
4/13/2004	Norman W. Thompson, MD, PhD	The Screening and Management of Pancreatic Neuroendocrine Tumors in Patients with MEN1
4/6/2004	Daniel D. Von Hoff, MD	Pursuing Therapeutic Targets That Aren't There
2/24/2004	Kathryn Zoon, PhD	Human Interferon Alpha: Clinical Diversity and Still an Enigma
2/17/2004	Richard G. Pestell, MD, PhD	Nuclear Receptors and Cyclins in Hormone Signaling
2/10/2004	Thomas J. Walsh, MD	Echinocandins: A New Advance in Infectious Diseases Supportive Care from Bench to Bedside
2/3/2004	V. Craig Jordan, OBE, PhD, DSc	Estrogen-Induced Apoptosis to Kill the Cancer But Not the Patient
1/27/2004	Albert J. Fornace, Jr, MD	The Case for p38 MAP Kinase as a Tumor Suppressor: New Targets for Cancer Therapeutics
1/20/2004	Larry O. Arthur, PhD	Basic Research Leading to an Inactivated Viral Vaccine
1/13/2004	Michael B. Kastan, MD,PhD	The ATM Signaling Pathway: Importance in Cancer Development and Therapy
1/6/2004	Jeffrey Schlom, PhD	Design and Development of Recombinant Vaccines for Cancer Therapy
12/16/2003	Carlos L. Arteaga, MD	The ErbB Network as a Therapeutic Strategy in Human Neoplasia
12/9/2003	Kenneth W. Kinzler, MD	Molecular Analyses of Colorectal Cancer
12/2/2003	John M. Goldman, FRCP	Chronic Myeloid Leukaemia: Some Progress Towards Cure?
11/25/2003	Lorraine J. Gudas, PhD	Stem Cells, Retinoids, and Cancer Therapy
11/18/2003	Robert Yarchoan, MD	AIDS Malignancies: Opportunities for the Targeted Therapy of Opportunistic Tumors
11/4/2003	Larry Kwak, MD, PhD	Translational Development of Therapeutic Lymphoma Vaccines
10/28/2003	Steven K. Libutti, MD	AIDS Vaccines: Basic Science to Clinical Applications
10/21/2003	Michael B.Sporn	The NCI: A Bridge for Genesis and Transduction of New Ideas in Cancer Prevention and Treatment
10/7/2003	Peter L. Choyke, MD	NCI's Molecular Imaging Program
9/30/2003	Ronald G. Crystal, MD	Genetic Medicine Strategies to Augment Host Defenses Against Cancer
9/23/2003	(1) Lance Liotta, MD, PhD (2) Emanuel Petricoin, PhD	Clinical Proteomics: Application to Early Diagnosis and Individualized Therapy of Cancer
9/16/2003	Shiv Grewal, PhD	RNAi-mediated Epigenetic Control of Genome: Implications for Cancer Biology
9/9/2003	H. Richard Alexander,MD	Experience with High Dose Tumor Necrosis Factor in Cancer Treatment Using Vascular and Perfusion Techniques
7/29/2003	Joe W. Gray, PhD	Cancer Genomics: Recurrent Events, Mechanisms and Targets
7/22/2003	Frank M. Balis, MD	Central Nervous System Pharmacology of Anti-Cancer Drugs
7/8/2003	Moshe Talpaz, MD	CML: Evolution of Therapy and Emerging Questions
7/1/2003	John T. Isaacs, PhD	Rational Drug Therapy for Prostate Cancer Based on Its Unique Biology
6/24/2003	Lee J. Helman, MD	Metastatic Signalling Pathways in a Mouse Osteosarcoma Model
6/17/2003	Todd R. Golub, MD	Genomic Information and Cancer
5/27/2003	Rachel Ballard-Barbash, MD	Energy Balance and Cancer: Risk and Prognosis
5/20/2003	Karen Antman, MD	New Developments in Sarcomas
5/13/2003	Derek LeRoith, MD, PhD	The Role of Insulin-like Growth Factors in Cancer
5/6/2003	Anita B. Roberts, PhD	Smad3: A Major Player in Pathogenetic Effects of TGF-beta
4/29/2003	Michail V. Sitkovsky, PhD	Tumor Defense Countermeasures: The Anti-Purinergic Strategy for Therapy of Cancer
4/22/2003	Neil Caporaso, MD	Controversies in the Genetics of Lung Cancer
4/17/2003	Terumi Kohwi-Shigematsu, PhD	Tissue-specific Nuclear Architecture and Gene Function Regulated by a Single Protein SATB1
4/15/2003	Ann Thor, MD	Hormonal and Dietary Modification of Mammary Development and Carcinogenesis Using a Transgenic Model System
4/1/2003	Yves Pommier, MD, PhD	Targeting DNA Topoisomerase I and Its Downstream Targets for Cancer Therapies
3/25/2003	Thomas Reid, MD	Aneuploidy and Cancer: Cause or Consequence?
3/18/2003	John M. Coffin, PhD	HIV Evolution and Drug Resistance
3/11/2003	Gary K. Schwartz, MD	Development of Cell Cycle Inhibitors for Cancer Therapy
3/4/2003	Louis M. Staudt, MD, PhD	Molecular Diagnosis and Molecular Targets in Cancer By Gene Expression Profiling
2/25/2003	Emil J. Freireich, M.D., D. Sc. (Hon.)	Bedside to Bench and Back: The Impact of Therapeutic Research on the Understanding of Cancer Biology
2/18/2003	Yves Pommier, M.D., Ph.D.	Targeting DNA Topoisomerase I and its Downstream Targets for Cancer Therapies
2/11/2003	Patricia Ganz, M.D.	Breast Cancer: A Model for Cancer Survivorship Research
2/4/2003	Issiah Fidler, D.V.M., Ph.D.	Anit-Vascular Therapy of Cancer Metastasis